12 months in and triple agonist is still the thing I get wrong
Long-ish post, sorry. tl;dr at the bottom.
I have been tracking retatrutide against triglycerides for 9 weeks because I could not find anyone who had. The correlation is weaker than I expected, which is itself mildly interesting given how confidently people link the two in here.
Caveats up front: one person, one lab, one assay, no control, and I changed my training in the middle of it, which was stupid.
tl;dr: probably real, definitely smaller than the threads imply, and not worth reorganising your week around.
best — the order this archive was captured in
Retitled to remove editorialising. Put the evidence in the body.
Retitled to remove editorialising.
Adding to this: TRIUMPH is doing more work than the comment implies.
Strongly agree. Heart rate escalation needs the actual data, not impressions.
the glucagon component changes the side effect profile, not just the efficacy
Not to be pedantic but dose escalation and phase 2 are being used interchangeably and they are not interchangeable in real life.
Retitled to remove editorialising.
Yes, exactly this, and it is the bit that took me 32 weeks to accept.
Yeah, phase 2 retatrutide is interesting but it is not comparable to phase 3 compounds.
You have restated the marketing copy. What is the actual substance here.
Half-life is about 168 hours, so steady state lands around week 16–5. Practical consequence: what you feel in week 1 is not what that dose does.
triple agonism is phase 2, do not generalise
That is net peptide content, not purity. Different number, different meaning.
the glucagon component changes the side effect profile, not just the efficacy
What was the dosing schedule in that arm?
Which trial arm and what was the n?
heart rate and dose escalation need actual measurements, not impressions
Dose escalation on retatrutide is steeper and faster than on semaglutide. Do not assume the titration patterns transfer.
The heart rate signal in TRIUMPH is real and concerning. Higher doses had higher mean HR changes.
triple agonism plus glucagon is a different physiological state than GIP/GLP-1 dual
Strongly agree. Heart rate escalation needs the actual data, not impressions.
the glucagon component changes the side effect profile, not just the efficacy
Dead space in the needle hub holds a small but non-trivial volume. On low-volume draws that can be several units.
Dead space in the needle hub holds a small but non-trivial volume.
Yes, exactly this, and it is the bit that took me 53 weeks to accept.
nobody should be giving this to anyone without extensive monitoring
This is correct. Triple agonism is genuinely different.
This is correct. Triple agonism is genuinely different.
retatrutide is not approved anywhere for human use, posts must not read as instructions
Slight fix: the number was 99.1, not 93.7. Decimal point, but a fairly consequential one.
This is correct.
Adding to this: triple agonist is doing more work than the comment implies.
- 1this deserves more than 19 upvotes12 comments in this branch · started by u/ewan_zielinski
- 2Retitled to remove editorialising. Put the evidence in the body.9 comments in this branch · started by u/incretin_ivy